Navigation Links
Pancreatic cancer: Researchers find drug that reverses resistance to chemotherapy
Date:9/24/2009

Berlin, Germany: For the first time researchers have shown that by inhibiting the action of an enzyme called TAK-1, it is possible to make pancreatic cancer cells sensitive to chemotherapy, opening the way for the development of a new drug to treat the disease.

Dr Davide Melisi told Europe's largest cancer congress, ECCO 15 ESMO 34 [1], in Berlin today (Thursday 24 September) that resistance to chemotherapy was the greatest challenge to treating pancreatic cancer.

"Pancreatic cancer is an incurable malignancy, resistant to every anti-cancer treatment. Targeting TAK-1 could be a strategy to revert this resistance, increasing the efficacy of chemotherapy," said Dr Melisi, who until the start of September was a Fellow at the M.D. Anderson Center in Houston (Texas, USA); he has now moved to a staff position at the National Cancer Institute in Naples (Italy). "During the past few years we have been studying the role played by a cytokine or regulatory protein called Transforming Growth Factor beta (TGFbeta) in the development of pancreatic cancer. Recently we focused our attention on a unique enzyme activated by TGFbeta, TAK-1, as a mediator for this extreme drug resistance."

Dr Melisi and his colleagues investigated the expression of TAK-1 (TGFbeta-Activated Kinase-1) in pancreatic cell lines and developed a drug that was capable of inhibiting TAK-1. They tested the activity of the TAK-1 inhibitor on its own and in combination with the anti-cancer drugs gemcitabine, oxaliplatin and SN-38 (a metabolite of the anti-cancer drug irinotecan) in cell lines, and the activity of the TAK-1 inhibitor combined with gemcitabine against pancreatic cancer in mice.

"The use of this TAK-1 inhibitor increased the sensitivity of pancreatic cells to all three chemotherapeutic drugs. By combining it with classic anti-cancer drugs, we were able to use doses of drugs up to 70 times lower in comparison with the control to kill the same number of cance
'/>"/>

Contact: Emma Mason
wordmason@mac.com
ECCO-the European CanCer Organisation
Source:Eurekalert

1

GOOD

Page: 1 2

Related medicine news :

1. The Lustgarten Foundation Expresses Condolences as Pancreatic Cancer Claims Life of Myles Brand
2. The Lustgarten Foundation Says Patrick Swayzes Death Highlights the Need for Increased Research into Early Diagnosis and Treatment of Pancreatic Cancer
3. The Pancreatic Cancer Action Network Is Saddened by the Death of Actor Patrick Swayze
4. MicroRNAs circulating in blood show promise as biomarkers to detect pancreatic cancer
5. Pancreatic Cancer Deaths Higher for Blacks
6. Blood Test May Spot Pancreatic Cancer Early
7. Blood Flow Mismatch Seen in Pancreatic Cancers
8. Abnormal Protein May Signal Pancreatic Cancer
9. Blood Type May Boost Pancreatic Cancer Risk
10. Metformin May Lower Diabetics Odds for Pancreatic Cancer
11. Pancreatic cancer risk decreased by one anti-diabetic therapy, increased by others
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... Utah (PRWEB) May 18, 2013 ... on insurance agents’ role in Marketplaces . ... to traditional employer sponsored health benefits, is the ... and health reimbursement arrangements . , ... Health and Human Services (HHS) recently released a ...
(Date:5/18/2013)... May 18, 2013 The Communities of ... special places we call home. These are the townships, villages ... are the locations where the people are friendly and neighbors ... viewers off the highways and shares the best in both ... nations with an American sports and film celebrity. It airs ...
(Date:5/18/2013)... “World Healthcare IT Market: Trends & Forecast (2010 – ... and opportunities in North America, Europe, Asia, & Rest ... 89 market data tables , 20 ... , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , Early buyers will ... IT market is expected to grow from $99.6 billion ...
(Date:5/18/2013)... FL (PRWEB) May 18, 2013 TheBeautyPlace.com ... Nioxin. Pattern hair loss is not a result of ... According to Men’s Fitness Magazine, 70% of men suffer ... Professional Strength is renowned for hair transplant surgery, ... fights male pattern baldness known as Bosley Professional Strength. ...
(Date:5/18/2013)... New York, New York (PRWEB) May 18, 2013 ... continue to mount in courts throughout the country, Bernstein ... that metal-on-metal hip replacement patients often suffer tissue damage ... During the study, which according to Science Daily will ... 69 metal-on-metal hip replacement recipients underwent MRI screens of ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Communities of Distinction TV Presents "A Place to Call Home" Segment 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4
... a catastrophic epidemic of smoking deaths, which is expected to cause ... including one in five of all male deaths and one ... male bidi smokers lose about six years of life, female bidi ... ten years. , The findings are from the first nationally ...
... ReBuilder Medical,Technologies, Inc. (Pink Sheets: RBRM), ... for diabetic peripheral neuropathy, Molluscum,Contagiosum, and MRSA, ... year, details,are available on their Annual Report ... http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO ), "The company,s growth ...
... German trial could be a breakthrough treatment in vascular ... stents haven,t worked well for blocked leg arteries, but ... balloons, which are inserted at the end of catheters ... whose balloons were coated with paclitaxel, one of the ...
... Approves Stock Repurchase Program, Raising 2008 EPS Guidance to $2.58 to $2.73 ... ... BEACH, Va., Feb. 13 AMERIGROUP,Corporation (NYSE: AGP ) today announced ... $31.1 million, or $0.57 per diluted,share, versus net income of $29.9 million, ...
... Feb. 13 Watson,Pharmaceuticals, Inc. (NYSE: WPI ... the U.S. Food and Drug Administration ("FDA"),has initiated ... regarding the duration or outcome of the inspection ... Florida manufacturing facility has,been under Official Action Indicated ...
... trauma disorder as good a marker for health status as ... People with post-traumatic stress disorder (PTSD) are as likely to ... disease risk factors, a new study suggests. , The findings, ... of Nervous and Mental Disease , come from examining the ...
Cached Medicine News:Health News:India caught in catastrophic smoking epidemic 2Health News:India caught in catastrophic smoking epidemic 3Health News:ReBuilder Medical Technologies, Inc. Announces 2007 Sales Nearly Doubled Sales in 2006 2Health News:Drug-Coated Balloons Keep Leg Arteries Open: Study 2Health News:Drug-Coated Balloons Keep Leg Arteries Open: Study 3Health News:AMERIGROUP Reports Q4 Net Income of $31.1 Million or $0.57 Per Diluted Share; Full-Year Net Income of $116.5 Million or $2.16 Per Diluted Share 2Health News:AMERIGROUP Reports Q4 Net Income of $31.1 Million or $0.57 Per Diluted Share; Full-Year Net Income of $116.5 Million or $2.16 Per Diluted Share 3Health News:AMERIGROUP Reports Q4 Net Income of $31.1 Million or $0.57 Per Diluted Share; Full-Year Net Income of $116.5 Million or $2.16 Per Diluted Share 4Health News:AMERIGROUP Reports Q4 Net Income of $31.1 Million or $0.57 Per Diluted Share; Full-Year Net Income of $116.5 Million or $2.16 Per Diluted Share 5Health News:AMERIGROUP Reports Q4 Net Income of $31.1 Million or $0.57 Per Diluted Share; Full-Year Net Income of $116.5 Million or $2.16 Per Diluted Share 6Health News:AMERIGROUP Reports Q4 Net Income of $31.1 Million or $0.57 Per Diluted Share; Full-Year Net Income of $116.5 Million or $2.16 Per Diluted Share 7Health News:AMERIGROUP Reports Q4 Net Income of $31.1 Million or $0.57 Per Diluted Share; Full-Year Net Income of $116.5 Million or $2.16 Per Diluted Share 8Health News:AMERIGROUP Reports Q4 Net Income of $31.1 Million or $0.57 Per Diluted Share; Full-Year Net Income of $116.5 Million or $2.16 Per Diluted Share 9Health News:AMERIGROUP Reports Q4 Net Income of $31.1 Million or $0.57 Per Diluted Share; Full-Year Net Income of $116.5 Million or $2.16 Per Diluted Share 10Health News:AMERIGROUP Reports Q4 Net Income of $31.1 Million or $0.57 Per Diluted Share; Full-Year Net Income of $116.5 Million or $2.16 Per Diluted Share 11Health News:AMERIGROUP Reports Q4 Net Income of $31.1 Million or $0.57 Per Diluted Share; Full-Year Net Income of $116.5 Million or $2.16 Per Diluted Share 12Health News:AMERIGROUP Reports Q4 Net Income of $31.1 Million or $0.57 Per Diluted Share; Full-Year Net Income of $116.5 Million or $2.16 Per Diluted Share 13Health News:AMERIGROUP Reports Q4 Net Income of $31.1 Million or $0.57 Per Diluted Share; Full-Year Net Income of $116.5 Million or $2.16 Per Diluted Share 14Health News:AMERIGROUP Reports Q4 Net Income of $31.1 Million or $0.57 Per Diluted Share; Full-Year Net Income of $116.5 Million or $2.16 Per Diluted Share 15Health News:Watson Pharmaceuticals Announces FDA Inspection of Florida Facilities 2Health News:PTSD a Risk Factor for Long-Term Disease 2
(Date:5/17/2013)... , May 17, 2013  Sony Biotechnology Inc. ("Sony") ... 8-well strip holder and 130um sorting chip.  Sony will also ... on its new SH800 Cell Sorter, the EC800 flow cytometer, ... tutorials at CYTO 2013, which will be held at the ... San Diego, California , from May 20 - ...
(Date:5/17/2013)... 17, 2013  TechAtlas Group has announced the ... landscape map for the Chronic Kidney Disease (CKD) ... companies with drugs and devices currently on the ... sequelae. (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ... hypertension - renal denervation , diabetic nephropathy ...
(Date:5/17/2013)... Fuse Science, Inc. (OTCQB: DROP), ( www.fusescience.com ) ... new, patent-pending technologies poised to redefine how consumers receive energy, ... a business update teleconference and webcast for shareholders and the ... 4:30 PM ET. Fuse Science, Inc. CEO, ... and will be joined by Rubin Hanan ...
Breaking Medicine Technology:Sony Delivers New Technology for Science to CYTO 2013 2TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2
... AMSTERDAM, September 19, 2011 Agendia, ... that a published report highlighting the development and ... was published online in Breast Cancer Research ... a part of Agendia,s Symphony™ suite of breast ...
... Laser Med Center , which specializes in treating Trigeminal ... laser device. This is a non-invasive alternative to surgery, ... Trigeminal Neuralgia is a terribly painful condition of ... (the fifth cranial nerve or CN5) is primarily a ...
Cached Medicine Technology:Breast Cancer Research and Treatment Highlights Development and Validation of BluePrint® 2Breast Cancer Research and Treatment Highlights Development and Validation of BluePrint® 3FDA Approved, Non-Invasive Laser Is A Success in Trigeminal Neuralgia Pain Treatment 2
... temporary internal drainage from the ureteropelvic junction ... stricture. The segment with no sideports prevents ... preventing ingrowth of the ureteral wall to ... Intended for one-time use. CAUTION: Periodic evaluation ...
... for temporary internal drainage from the ureteropelvic ... a stricture. The segment with no sideports ... while preventing ingrowth of the ureteral wall ... packages. Intended for one-time use. CAUTION: Periodic ...
ACMI™ 4.8 Fr Closed Tip Ureteral Stents are easily inserted through the 5 Fr working port of an endoscope. Large internal lumens enhance urinary flow, promoting the kind of drainage you might o...
... Used for retrograde ... and subsequent ureteral stent ... has a radiopaque band ... to aid in fluoroscopic ...
Medicine Products: